Psoriasis: exploring the associated clinical issues and how to support your patients

April 2013
Journal of Aesthetic Nursing;Apr2013, Vol. 2 Issue 3, p112
Academic Journal
Although psoriasis is a common condition manifesting in the skin and joints, recent clinical evidence has shown health professionals that it is a systemic disease that is more than skin deep. The most recent guidelines from the National Institute for Health and Clinical Excellence (2012) on psoriasis offer a comprehensive evidence-base to psoriasis management. Aesthetic nurses have an important role with their clients who have psoriasis, in supporting them in coping with and treating psoriasis and having an awareness of how cosmetic treatments may affect psoriasis. This article aims to inform and update aesthetic nurses' knowledge of the psoriasis signs and symptoms, evidence-based treatment options and implications for cosmetic treatment.


Related Articles

  • Older people and psoriasis: the use of emollient therapy. Van Onselen, Julie // Nursing & Residential Care;Jul2013, Vol. 15 Issue 7, p476 

    No abstract available.

  • Fusion protein denileukin diftitox clears psoriasis. Kuznar, Wayne // Dermatology Times;Oct2001, Vol. 22 Issue 10, p18 

    Reports the effectiveness of dermatologic agents denileukin diftitox in clearing skin lesions in patients with psoriasis vulgaris in New York. Antipsoriatic activity of denileukin; Daily dosage administration; Decrease of lesional T-cells in the dermis.

  • Psoriasis.  // British Journal of School Nursing;Jun2014, Vol. 9 Issue 5, p222 

    The article offers information on the medical condition called psoriasis. Topics discussed include the physical symptoms and causes of psoriasis, the different types of psoriasis, and recommended treatments. It cites several topical treatments for the skin disease such as Calcipotriol vitamin D,...

  • Combo of Old, New Agents May. Mitchell Herald Personalized Psoriasis Tx, Deborah // Dermatology Times;Jul98, Vol. 19 Issue 7, p4 

    Presents several dermatologic drugs used in the treatment of psoriasis. Pharmacologic effects of drugs; Systemic agent options for the disease.

  • Emollient base delivers topical corticosteroids with better efficacy. Guttman, Cheryl // Dermatology Times;Dec2000, Vol. 21 Issue 12, p33 

    Recommends the use of topical corticosteroids with an emollient base to treat psoriasis. Comparison of outcomes and patient reactions using diflorasone diacetate emollient ointment versus diflorasone diacetate emollient cream; Effectiveness of topical corticosteroid treatment.

  • Antisense technology promises rational approach to psoriasis treatment. Nemec, John // Dermatology Times;Sep2001, Vol. 22 Issue 9, p15 

    Reports on the development of an antisense drug for the treatment of psoriasis in Salt Lake City, Utah. Application of antisense cream to targeted lesions; Inhibition of intercellular adhesion molecule through antisense administration; Absence of inflammatory response during treatment.

  • 'Wonder Drugs' for Psoriasis: A Never Ending Story. Mrowietz, Ulrich // American Journal of Clinical Dermatology;Mar/Apr2001, Vol. 2 Issue 2, p129 

    Discusses the popularity of `wonder drugs' or products of doubtful origin for the treatment of psoriasis. Dangerous characteristics of such drugs; Review of situations in which effectiveness of a product in psoriasis was due to the presence of undeclared potent corticosteroids; Lessons that can...

  • Calcipotriol Ointment: A Review of its Use in the Management of Psoriasis. Scott, L.J.; Dunn, C.J.; Goa, K.L. // American Journal of Clinical Dermatology;Mar/Apr2001, Vol. 2 Issue 2, p95 

    Calcipotriol, a vitamin D analog, acts not only to inhibit cell proliferation and enhance cell differentiation in the skin of patients with psoriasis, but also appears to have effects on immunologic markers that are thought to play a role in the etiology of the disease. In several well designed,...

  • Siplizumab studies show safety as psoriasis Tx. Hannapel, Coriene E. // Dermatology Times;Oct2001, Vol. 22 Issue 10, p16 

    Reports the safeness of dermatologic agents siplizumab for the treatment of psoriasis in San Francisco, California. Evidence on biologic activity based on dose dependent; Improvement of psoriasis as measured by the Psoriasis Area and Severity Index (PASI) score; Efficacy of PASI score in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics